Chris Starr, PhD
Dr. Starr is a veteran in the orphan disease world, having helped bring six orphan therapeutics to market. He was a co-founder of Biomarin Pharmaceutical, where he acted as the Chief Scientific Officer. He left Biomarin to start Raptor Pharmaceuticals in 1996, where was the Co-Founder, Chief Executive Officer, and Board Member through 2014. He continued as a valued member of the Board of Directors until its sale to Horizon Pharma in 2016. Prior to starting Biomarin, Dr. Starr was the VP of Research & Development at Glycol, Inc. Dr. Starr currently serves as the Co-Founder and Executive Chairman of Monopar Therapeutics LLC. He earned a BS at Syracuse University and a PhD at State University of New York.
Matthew J. Hogan has had an extensive career in the field of corporate finance, with a particular focus on healthcare. Mr. Hogan served as the Chief Financial Officer of DURECT Corporation from 2006 to October 2018, and continues to act as a corporate finance advisor to DURECT. Prior to joining DURECT, he was the Chief Financial Officer of Ciphergen Biosystems from 2000-2006, Chief Financial Officer of Avocet Medical from 1999-2000, and Chief Financial Officer of Microcide Pharmaceuticals from 1996-1999. Prior to making the shift to the CFO role, Mr. Hogan was an investment banker for Merrill Lynch from 1986 to 1996 during which time he did extensive financing and advisory work for biotechnology and pharmaceutical companies. Prior to joining Merrill Lynch, he was a commercial banker from 1983 to 1986 for Manufacturers Hanover Trust. Mr. Hogan earned a BA degree in Economics, cum laude, from Dartmouth College and his MBA from the Amos Tuck School of Business Administration.
Dr. Marcie Wood
Dr. Marcie Wood is a Senior Managing Scientist and Biopharmaceutical/Pharmaceutical Practice Director with ToxStrategies, Inc., located in Houston, Texas. She is a toxicologist with more than 14 years of experience in drug discovery and development, including 7 years at the U.S. Food and Drug Administration. As a former FDA pharmacology/toxicology reviewer and supervisor in the Center for Drug Evaluation and Research (CDER) and nonclinical consultant for biopharmaceutical/pharmaceutical companies, she has expertise in regulatory agency expectations for nonclinical toxicology/pharmacology programs for the development of drug products in numerous therapeutic areas. She has also been involved in therapeutic products being developed for orphan drug indications. Dr. Wood has extensive experience in nonclinical safety assessment studies evaluating unique or complex routes of administration for both biological and small molecule products. She also has experience in the design, monitoring, and data interpretation of animal (rodent and non-rodent) toxicology studies (GLP and non-GLP) and in authoring nonclinical sections (pharmacology, pharmacokinetics, toxicology) of regulatory documents (e.g., preIND, IND, BLA/NDA).